Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC6022-0004 · 1 trial · 2 indications
Measured as micromolar per hour (µM\*h).
Measured as micromolar (µM).
Measured as number of events.
Measured as number of events.
Measured as µM\*h.
Measured as number of events.
| Arm | Type | Description |
|---|---|---|
| NNC6022-0004 | EXPERIMENTAL | Participants will receive NNC6022-0004 administered orally as a single ascending dose (SAD), multiple ascending dose (MAD), or under fed/fasted conditions. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to NNC6022-0004 administered orally as a SAD, MAD, or under fed/fasted conditions. |
| Name | Type | Description |
|---|---|---|
| NNC6022-0004 | DRUG | Participants will receive single dose of NNC6022-0004 administered orally in capsule form. |
| Placebo | DRUG | Participants will receive placebo matched to NNC6022-0004 administered orally in capsule form. |
Inclusion Criteria: * Male, or female of non-childbearing potential. * For Parts A, B, C and D: Age 18-55 years (both inclusive) at the time of signing the informed consent. For optional Part E only: Age 18-65 years (both inclusive) at the time of signing the informed consent. -For Parts A, B, C ...
Top 20 of 32 competitors
NNC6022-0004 is an investigational small molecule being developed for obesity. It is also being studied in people with elevated high-sensitivity C-reactive protein (hsCRP), a marker of inflammation. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
NNC6022-0004 is being developed by Novo Nordisk A/S, a biopharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational drug in healthy volunteers and people living with obesity.
NNC6022-0004 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety profile.
NNC6022-0004 is being studied in a Phase 1 clinical trial registered as NCT07693868. This randomized, double-blind, placebo-controlled study is evaluating the safety of the drug in healthy people and people living with obesity. The trial is recruiting 128 participants in the Netherlands and is currently active.
Yes, NNC6022-0004 is being studied in people with obesity and elevated high-sensitivity C-reactive protein (hsCRP). The ongoing Phase 1 trial includes participants with these conditions to evaluate how safe the drug is in this population. The study is recruiting healthy volunteers as well as people with obesity.